Delving into the Latest Updates on Azilsartan Kamedoxomil with Synapse

主要试验目的研究空腹/餐后状态下单次口服受试制剂美阿沙坦钾片（规格：80mg，海南葫芦娃药业集团股份有限公司生产）与参比制剂美阿沙坦钾片（商品名：易达比®；规格：80mg；Takeda Ireland Ltd.生产）在健康受试者体内的药代动力学，评价空腹/餐后状态口服两种制剂的生物等效性。次要试验目的评估受试制剂美阿沙坦钾片（规格：80mg）与参比制剂易达比®（规格：80mg）在健康受试者中的安全性。

[Translation]

Main study objectives To study the pharmacokinetics of the test preparation, Asartan Potassium Tablets (Specification: 80 mg, produced by Hainan Huluwa Pharmaceutical Group Co., Ltd.) and the reference preparation, Asartan Potassium Tablets (trade name: Edabi®; Specification: 80 mg; produced by Takeda Ireland Ltd.) in healthy subjects after a single oral administration in the fasting/postprandial state, and to evaluate the bioequivalence of the two preparations in the fasting/postprandial state. Secondary study objectives To evaluate the safety of the test preparation, Asartan Potassium Tablets (Specification: 80 mg) and the reference preparation, Edabi® (Specification: 80 mg) in healthy subjects.

Start Date09 Sep 2024

Sponsor / Collaborator

Hainan Huluwa Pharmaceutical Group Co., Ltd.

TCTR20240616002 / Not yet recruitingPhase 1

Bioequivalence study of Azilsartan medoxomil 80 mg in healthy volunteer under fasting condition

Start Date01 Sep 2024

Sponsor / Collaborator

Unison Laboratories Co. Ltd.

100 Clinical Results associated with Azilsartan Kamedoxomil

Login to view more data

100 Translational Medicine associated with Azilsartan Kamedoxomil

Login to view more data

100 Patents (Medical) associated with Azilsartan Kamedoxomil

Login to view more data

702

Literatures (Medical) associated with Azilsartan Kamedoxomil

31 Dec 2024·Journal of enzyme inhibition and medicinal chemistry

Acetazolamide and human carbonic anhydrases: retrospect, review and discussion of an intimate relationship

Review

Author: Tsikas, Dimitrios

Acetazolamide (AZM) is a strong pharmacological sulphonamide-type (R-SO₂-NH₂, pK_a 7.2) inhibitor of the activity of several carbonic anhydrase (CA) isoforms, notably of renal CA II (K_i, 12 nM) and CA IV (K_i, 74 nM). AZM is clinically used for about eighty years in various diseases including epilepsy and glaucoma. Pharmacological AZM increases temporarily the urinary excretion of bicarbonate (HCO₃^-) and sodium ions (Na⁺) and sustainably the urinary pH. AZM is excreted almost unchanged over several hours at high rates in the urine. Closely parallel concentrations of circulating and excretory AZM are observed upon administration of therapeutical doses of AZM. In a proof-of-principle study, we investigated the effects of the ingestion of a 250-mg AZM-containing tablet by a healthy volunteer on the urinary excretion of organic and inorganic substances over 5 h (range, 0, 0.5, 1, 1.5, 2, 3, 4, 5 h). Measured analytes included: AZM, amino acids and their metabolites such as guanidinoacetate, i.e. the precursor of creatine, of asymmetrically (ADMA) and symmetrically (SDMA) dimethylated arginine, nitrite (O = N-O^-, pK_a 3.4) and nitrate (O₂N-O^-, pK_a -1.37), the major metabolites of nitric oxide (NO), the C-H acidic malondialdehyde (MDA; (CHO)₂CH₂, pK_a 4.5), and creatinine for correction of analytes excretion. All analytes were measured by validated isotopologues using gas chromatography-mass spectrometry (GC-MS) methods. AZM excretion in the urine reached its maximum value after 2 h and was fairly stable for the next 3 h. Time series analysis by the ARIMA method was performed. AZM ingestion increased temporarily the urinary excretion of the amino acids Leu + Ile, nitrite and nitrate, decreased temporarily the urinary excretion of other amino acids. AZM decreased sustainably the urinary excretion of MDA, a biomarker of oxidative stress (i.e. lipid peroxidation). Whether this decrease is due to inhibition of the excretion of MDA or attenuation of oxidative stress by AZM is unknown. The acute and chronic effects of AZM on the urinary excretion of electrolytes and physiological substances reported in the literature are discussed in depth in the light of its extraordinary pharmacokinetics and pharmacodynamics. Tolerance development/drug resistance to AZM in chronic use and potential mechanisms are also addressed.

01 Oct 2024·ECOTOXICOLOGY AND ENVIRONMENTAL SAFETY

Concentrations, probabilistic human and ecological risks assessment attribute to antibiotics residues in river water in China: Systematic review and meta-analysis

Review

Author: Li, Anhui ; Hui, Xiaomei ; Wang, Aihua ; Wang, Lu ; Li, Chao ; Chang, Sheng

Antibiotics residues even low concentrations increases human health risk and ecological risk. The current study was conducted with the aims of meta-analysis concentrations of antibiotics in river water including amoxicillin (AMX), tetracyclines (TCN), sulfamethoxazole (SMX), ciprofloxacin (CIP), trimethoprim (TMP), azithromycin (AZM) and amoxicillin (AMX) and estimates human health and ecological risks. Search was performed in databases including Scopus, PubMed, Web of Science, Embase, Science direct, Cochrane, Science Direct, Google Scholar were used to retrieve scientific papers from January 1, 2004 to June 15, 2024. The concentration of antibiotics residues was meta-analyzed using random effects model in water river water based on type of antibiotics subgroups. Human health risk assessment from ingestion and dermal contact routs was estimated using target hazard quotient (THQ), total target hazard quotient (TTHQ), carcinogenic (CR) and ecological hazard quotient (EHQ) of antibiotics in river water was estimated using monte carlo simulations (MCS) model. Sixty-two papers on antibiotics in river water with 272 data-reports (n = 28,522) were included. The rank order of antibiotics residues in river water based on pooled concentration was SMX (66.086 ng/L) > CIP (26.005 ng/L) > TCN (17.888 ng/L) > TMP (6.591 ng/L) > AZM (2.077 ng/L) > AMX (0.029 ng/L). The overall pooled concentration of antibiotics residues in river water was 24.262 ng/L, 95 %CI (23.110-25.413 ng/L). TTHQ for adults and children due to antibiotics in water was 2.41E-3 and 2.36E-3, respectively. The sort of antibiotics based on their quota in TTHQ for adults and children was AMX > CIP > TMP > AZM > TCN > SMX. Total CR in adults and children was 2.41E-03 and 2.36E-03, respectively. The sort of antibiotics based on percentile 95 % EHQ was SMX (7.70E+03) > TCN (7.63E+01) > TMP (7.03E-03) > CIP (2.86E-03) > AMX (5.71E-04) and TEHQ values due to antibiotics in river water in China was equal to 7.78E+03. Current study suggests that conduct effective monitoring and water quality control plans to reduce concentration of antibiotics especially SMX, TCN, and CIP in river water of China.

01 Sep 2024·INTERNATIONAL IMMUNOPHARMACOLOGY

Combinational therapy of mesenchymal stem cell-derived extracellular vesicles and azithromycin improves clinical and histopathological recovery in CLP sepsis model

Article

Author: Soufihasanabad, Sara ; Ahangari, Fatemeh ; Mirsanei, Zahra ; Soudi, Sara ; Ghaffari Khaligh, Sahar ; Ebadi Asl, Pedram ; Mahmoud Hashemi, Seyed

BACKGROUND:

Sepsis is a syndrome that occurs following an infection and marked by severe inflammatory responses, and if not treated in time, it can lead to multi-organ failure syndrome and death. This study examines the effects of a novel combination therapy using azithromycin and mesenchymal stem cell-derived extracellular vesicles (EVs) on a cecal ligation and puncture (CLP) model of sepsis.

METHODS:

Human Wharton's jelly-mesenchymal stem cells were cultured, characterized, and used to extract EVs. The CLP sepsis model was induced in mice, followed by treatments: saline, AZM, EVs, and combination therapy (A+E). Clinical sepsis scores were recorded 24 h post-treatment. Serum, peritoneal fluid, and organ tissues (kidney, liver, lung) were collected and analyzed for biochemical parameters (AST ALT, and creatinine), inflammatory markers, bacterial load, and histopathological changes.

RESULTS:

The A+E combined treatment improved the clinical scores of septic mice. The administration of A+E reduced bacterial loads in the peritoneum of septic mice, contributing to effective control of infection. Inflammatory markers of neutrophils-to-lymphocytes ratio (NLR) and TNF-α serum levels were significantly lower in the combinational therapy group, indicating significant anti-inflammatory effect of this combination. Additionally, combination of AZM and EVs alleviated organ damage mainly within liver, kidneys and lungs. Based on histopathological assessments and biochemical parameters, there was diminished tissue damage as well as reduced inflammation, which is correlated with improved functions of these vital organs.

CONCLUSION:

The combined use of azithromycin and EVs offers a promising therapeutic approach for sepsis by effectively controlling infection and modulating the inflammatory response.

1

News (Medical) associated with Azilsartan Kamedoxomil

26 Jul 2017

·www.bioportfolio.com

Arbor Pharmaceuticals LLC Pharmaceuticals Healthcare Deals and Alliances Profile. [Report Updated: 20072017] Prices from USD $250

Summary Arbor Pharmaceuticals LLC Arbor is a healthcare products provider that develops prescription products for the hospital, cardiovascular and pediatric segments. The company offers licensing, manufacturing, development and commercialization of latestage prescription products. It also offers generic prescription and development stage products. Arbor's prescription products comprise edarbi, edarbyclor, bidil, nymalize, eryped, and erythromycin group of products. It offers products used in treatment areas including cardiovascular, emergency, pediatrics, psychiatry and endocrinology diseases. The company offers its products through sales professionals to hospitals and physicians across the US. Arbor is headquartered in Atlanta, Georgia, the US. Arbor Pharmaceuticals LLC Pharmaceuticals Healthcare Deals and Alliances Profile. provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions MAs, partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, subsector and regions. GlobalData derived the data presented in this report from proprietary inhouse Pharma eTrack deals database, and primary and secondary research. Scope Financial Deals Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships. Deals by Year Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period. Deals by Type Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc. Deals by Region Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America. Deals by Subsector Chart and table showing information on the number of deals and value reported by the company, by subsector. Major Deals Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's major public companies key financial metrics and ratios. Business Description A brief description of the company's operations. Key Employees A list of the key executives of the company. Important Locations and Subsidiaries A list and contact details of key centers of operation and subsidiaries of the company. Key Competitors A list of the key competitors of the company. Key Recent Developments A brief on recent news about the company. Reasons to Buy Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period. Understand the company's business segments' expansion / divestiture strategy The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy. Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios. Equip yourself with detailed information about the company's operations to identify potential customers and suppliers. The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors. Stay uptodate on the major developments affecting the company Recent developments concerning the company presented in the profile help you track important events. Gain key insights into the company for academic or business research Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs. Note*: Some sections may be missing if data is unavailable for the company.

Acquisition

100 Deals associated with Azilsartan Kamedoxomil

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
-	Azilsartan Kamedoxomil	C09CA09	DB08822

R&D Status

Approved

10 top approved records.

Login

to view more data

Indication	Country/Location	Organization	Date
Essential Hypertension	EU	Takeda Pharma A/S	07 Dec 2011
Essential Hypertension	IS	Takeda Pharma A/S	07 Dec 2011
Essential Hypertension	LI	Takeda Pharma A/S	07 Dec 2011
Essential Hypertension	NO	Takeda Pharma A/S	07 Dec 2011
Hypertension	US	Azurity Pharmaceuticals, Inc.	25 Feb 2011

Developing

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Diabetes Mellitus, Type 2	Phase 3	US	Takeda Pharmaceutical Co., Ltd.	01 Jan 2012

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT02541669 (CTgov)	Phase 1	-	64	TAK-491 (Open Label: TAK-491 40 mg)	qxnuisvvnr(cldudiswkd) = uhkhfoywbz epfliufrdm (mkbczoheev, pegsfrkvnx - zyrtybpmhm) View more	-	05 Feb 2020
				TAK-491 (Open Label: TAK-491 80 mg)	qxnuisvvnr(cldudiswkd) = jesjovsbvs epfliufrdm (mkbczoheev, jgcndbdvng - dgitqbuxto) View more
NCT02517866 (CTgov)	Phase 4	Diabetes Mellitus, Type 2 \| Essential Hypertension	380	Azilsartan Medoxomil	zcajtxygna(dmqbmvoxdt) = qqcmlbpfqy wnhtnpsvtm (minhumawrx, kjctnsijyo - imszygjalr) View more	-	01 Mar 2019
NCT02480764 (CTgov)	Phase 3	Essential Hypertension	612	Valsartan Placebo+Azilsartan medoxomil (Azilsartan Medoxomil 40 mg)	phdbzeceic(exzpsbvmmv) = iwppevvjou qlzfojrhbp (dcmgqkyejl, nikzvtvjrc - rervqvtjrx) View more	-	11 Feb 2019
				Valsartan Placebo+Azilsartan medoxomil (Azilsartan Medoxomil 80 mg)	phdbzeceic(exzpsbvmmv) = mrbebatezv qlzfojrhbp (dcmgqkyejl, ftsbbcbdez - ccixoxulfi) View more
NCT02203916 (CTgov)	Phase 3	Essential Hypertension	328	Azilsartan medoxomil placebo (Placebo)	plzelsuwhg(uxpmgsltbj) = fuxhkhfzfa bsanryqyyn (bkvgwiuoia, eiaelayuwi - knugvmhajz) View more	-	19 Dec 2016
				Azilsartan medoxomil (Azilsartan Medoxomil 40 mg)	plzelsuwhg(uxpmgsltbj) = zjogmzihvs bsanryqyyn (bkvgwiuoia, rfyarwicig - pjdmnlqwse) View more
NCT00695955 (Pubmed \| Clin Exp Hypertens) Manual	Phase 3	Essential Hypertension	669	chlorthalidone+azilsartan medoxomil	kvgyvguzsz(lwhxhfoijr) = ampfgyeqcz ddqejlzffb (neyuxwkhqo ) View more	Positive	01 Jan 2016
				hydrochlorothiazide+azilsartan medoxomil	kvgyvguzsz(lwhxhfoijr) = roucjhnvzj ddqejlzffb (neyuxwkhqo ) View more
NCT01496430 (CTgov)	Phase 3	Diabetes Mellitus, Type 2 \| Hypertension	105	Placebo (Placebo QD)	xulxjbfvoe(pqveshfnps) = xuotjzvngm bngxrgmbun (kpzuapjawm, ibpkkuxugr - yrvqhdjake) View more	-	06 May 2015
				Azilsartan medoxomil (Azilsartan Medoxomil 40 mg QD)	xulxjbfvoe(pqveshfnps) = ekbzzcbngy bngxrgmbun (kpzuapjawm, rwbywrsgcn - xeataigino) View more
NCT00696384 (Pubmed) Manual	Phase 3	Hypertension	418	Azilsartan Medoxomil	ihonscbadx(trwvtnjkei): difference = -7.8 (95% CI, -9.8 to -5.8), P-Value = <0.001 View more	Positive	01 Mar 2015
				Azilsartan Medoxomil+Chlorthalidone
NCT01078376 (CTgov)	Phase 1	Hypertension	29	Azilsartan medoxomil (TAK-491)	uoctvrrxye(ghrbssgazw) = hqvqnwnnys pedirqmsii (qyhxuoglng, zasscmjjkc - uaubrcgusz) View more	-	25 Jul 2014
NCT00696384 (CTgov)	Phase 3	Essential Hypertension	418	Azilsartan Medoxomil (Azilsartan Medoxomil QD - Double Blind Reversal Phase)	vlzyfxveag(oiegfamxzd) = fiyqvowzjb wjfttnhhve (djlfyunpjl, jucxkqnibi - yosltanmql) View more	-	04 Jan 2012
				Placebo (Placebo QD - Double Blind Reversal Phase)	vlzyfxveag(oiegfamxzd) = nyaiyokqop wjfttnhhve (djlfyunpjl, hqkfhjhyed - oswibqojlk) View more
NCT00591578 (Pubmed \| J Clin Hypertens (Greenwich))	Phase 3	Essential Hypertension	984	Azilsartan medoxomil (AZL-M)	onfahsxxgj(jkojfdurvv) = puadfvqzgy ipqoqrmxoc (erpffnmqqv )	Positive	01 Jul 2011
				Valsartan (VAL)	onfahsxxgj(jkojfdurvv) = fcooborqqa ipqoqrmxoc (erpffnmqqv )